Form 4: Vivos Therapeutics Director Matthew Thompson Acquires 4,000 Stock Options
SEC Form 4
Director Matthew Thompson reports acquisition of 4,000 stock options in Vivos Therapeutics, Inc.
Summary
- On June 28, 2024, Matthew Thompson, a director of Vivos Therapeutics, Inc., filed a Form 4.
- The form reports a transaction on June 20, 2024, where Thompson acquired 4,000 stock options with an exercise price of $2.38.
- One-half of the options vested immediately, one-fourth will vest on September 30, 2024, and one-fourth will vest on December 31, 2024.
- Following the reported transaction, Thompson directly owns 7,067 derivative securities.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it is a standard disclosure of stock option grants to a company director.
Industry Context
This filing is a routine disclosure related to insider transactions and provides transparency to investors regarding the holdings of company directors.
Stakeholder Impact
- The granting of stock options aligns the director's interests with those of the shareholders.
Key Dates
| Date | Description |
|---|---|
| 06/20/2024 | Date of stock option grant. |
| 06/20/2024 | One-half of the options vested immediately. |
| 09/30/2024 | One-fourth of the options will vest. |
| 12/31/2024 | One-fourth of the options will vest. |
| 06/20/2029 | Expiration date of the stock options. |
| 06/28/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.